Keywords:
European Medicines Agency (EMA); antimicrobial stewardship (AMS); artificial intelligence; ethic; ethic and development; medical AI governance; pharmaceutical validation; regulatory drug development.
Grants and funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.